NR and Exercise for Blood Pressure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Brisk walking, Nicotinamide Riboside 1000 mg, Placebo.
- Who it may be relevant to
- Registry conditions: Hypertension (HTN). Basic parameters: 55 years — 80 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Ten-Week Oral Nicotinamide Riboside Supplementation With Aerobic Exercises on Blood Pressure in Post- Menopausal Women With Elevated/Stage I Hypertension
Overview
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets. Age-associated endothelial dysfunction and arterial stiffness are recognized as the key contributors to the development of hypertension and the unique role of nicotinamide adenine dinucleotide (NAD) depletion in the pathogenesis of vascular dysfunction has been recently discovered. Treatment with nicotinamide riboside (NR), an NAD precursor, has shown promise in preliminary clinical trials for improving blood pressure and vascular health in at-risk populations. In parallel, aerobic exercise is a well-established non-pharmacologic intervention known to improve cardiovascular outcomes. Emerging studies suggest that exercise may modulate NAD biosynthesis pathways, pointing toward a synergistic potential when combined with NAD-boosting strategies. However, clinical data evaluating the combined effects of NR supplementation and aerobic exercise remain scarce. Our randomized, placebo-controlled, four-arm, parallel-group design seeks to address this gap. The investigators will investigate the independent and combined effects of 10-week NR supplementation and brisk walking on blood pressure and vascular health in post-menopausal women with elevated/stage I hypertension. This population is specifically targeted due to their heightened risk for vascular dysfunction post-menopause and the observed responsiveness to NR-based interventions in prior studies. The investigators believe the findings from this trial will provide insight into the feasibility, safety, and efficacy of combining NAD-boosting supplementation with structured exercise in a uniquely vulnerable and previously understudied population. The potential to identify a low-risk, non-pharmaceutical therapeutic approach holds strong implications for public health, particularly in aging women with early-stage hypertension.
Interventions
- Behavioral Brisk walking
Brisk walking twice per week - Dietary supplement Nicotinamide Riboside 1000 mg
Nicotinamide Riboside supplementation 1000 mg per day - Other Placebo
Placebo
Primary outcome measures
- Blood pressure [Time frame: From enrollment to the end of follow-up at 20 weeks]
Secondary outcome measures (12)
- Whole Blood NAD concentration [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Endothelin 1 [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Angiotensin [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Body mass [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Fat mass [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Fat-free mass [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Fat percentage [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Height [Time frame: From enrollment to the end of follow-up at 20 weeks]
- BMI [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Waist Circumference [Time frame: From enrollment to the end of follow-up at 20 weeks]
- Seven-day accelerometry [Time frame: From enrollment to the end of follow-up at 20 weeks]
- 30-second chair stand test [Time frame: From enrollment to the end of follow-up at 20 weeks]
Eligibility criteria
Inclusion criteria
- women absent of menstruation for over one year,
- Chinese, and
- fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e., blood pressure ≥120/80 mmHg based on an average of ≥2 readings obtained on ≥2 occasions)
Exclusion criteria
- presence of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders,
- a history of hysterectomy,
- current use of vitamin B supplements and/or NAD precursors,
- ongoing hormone replacement therapy within the past six months,
- any changes in antihypertensive medication type or dosage within the last three months, or
- engagement in regular physical activity, defined as at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous-intensity exercise per week, during the three months prior to enrollment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07475208 · NTEC-2025-596